… Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by …
morbidity in association with the presence of antiphospholipid antibodies. The prevalence of APS …

… history of thrombosis (secondary prevention). Assessment … secondary prevention of venous
thromboembolism (VTE) have been evaluated in clinical trials, studies in primary prevention …

… Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome
and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; …

… In the setting of secondary prevention for noncardioembolic ischemic stroke or TIA, the …
various agents in the setting of secondary stroke prevention have recently been determined by …

… morbidity and the presence of antiphospholipid antibodies. Direct oral … prevention of
thrombosis and we wish to evaluate DOACs compared with VKAs in secondary prevention …

… of antiphospholipid syndrome. Anticoagulation remains the cornerstone in the management
of antiphospholipid syndrome… secondary thromboprophylaxis in antiphospholipid syndrome. …

Background: Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized
by thrombosis, pregnancy morbidity, and the presence of characteristic antibodies. Current …

… (Plavix) have been used for secondary prevention after noncardioembolic strokes or TIAs. …
-resistant APS patients for secondary thrombosis prevention. Based on our retrospective …

… In the RAPS trial, rivaroxaban was compared to warfarin over a 6-month period of time for
the secondary prevention of venous thrombosis (randomized but open-label study), N = 116 …

… We focused on the secondary prevention of stroke with APS, and compared single antiplatelet
therapy and a combination of antiplatelet and anticoagulation therapy in ischemic stroke …